PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

16 Jan 2019 16:52

RNS Number : 3076N
Collagen Solutions PLC
16 January 2019
 

 

16 January 2019

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Director / PDMR Dealing

 

The Company today announces that, Hilary Spence, Chief Financial Officer ("CFO") of the Company, was granted options (the "Options") over 1,000,000 ordinary shares of 1 pence each in the share capital of the Company ("Shares") exercisable at a price of 3.85 pence per Share.

 

The Options will vest in three equal tranches on the first, second and third anniversaries of 3 January 2019. Such vesting will be conditional on her continued employment. In addition, the ability to exercise any vested Options will be dependent on achieving a closing middle market price per Share of 10 pence at any time after the date of grant and on the Company delivering sustainable positive cash flows from operations for any period of six months. All Options will lapse after 10 years from the date of grant, being 16 January 2019.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hilary Spence

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions Plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

Identification code

Ordinary shares of 1p each

 

 

 

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Grant of options over ordinary shares of 1p each exercisable at 3.85p per share

c)

Price(s) and volume(s)

 

Price(s): Volume(s):

 

0 pence 1,000,000

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

N/A

 

 

N/A

e)

Date of the transaction

16/01/2019

f)

Place of the transaction

Outside a trading venue

 

 

For further information please contact:

 

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Steve Cox (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHCKADQABKDCDD
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.